Skip to content

Role of homoeopathic medicines for lowering anti-CCP levels in rheumatoid arthritis

A prospective clinical study to evaluate the role of individualized homoeopathic medicine on changes in anti- cyclic citrullinated peptide levels and clinical symptoms in patients with rheumatoid arthritis. - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/081755
Enrollment
38
Registered
2025-03-06
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M057- Rheumatoid arthritis with rheumatoid factor without organ or systems involvement

Interventions

Sponsors

National Institute of Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Cases fulfilling the diagnostic criteria of rheumatoid arthritis (ICD 10 M06.9) according to ACR OR ELAR score more than or equal to 6 out of 10 2.Cases with anti-CCP value above 20 IU per ml. 3.Patients in the age group of 18 to 65 years 4.Patients of all sexes, Religions and socio economic conditions 5.Patients who have not taken any treatment in the last 4 weeks for rheumatoid Arthritis 6.Patients who are willing to give written informed consent. 7.Patients who can read/ understand either English, Hindi, Bengali.

Exclusion criteria

Exclusion criteria: 1.Rheumatoid arthritis associated with complicated systemic diseases 2.Patients who are diagnosed with life threatening diseases, uncontrolled systemic illness, immune compromised states, psychiatric illness and malignancy 3.Patients not willing to undergo any investigation, if needed. 4.Patients on NSAIDs or DMARDs. 5.Pregnant women and lactating mothers. 6.Patients with substance abuse and or dependence 7.Patients who have been under homoeopathic treatment within in 3 months for any chronic illness.

Design outcomes

Primary

MeasureTime frame
By measuring changes in Anti CCP levelsTimepoint: At baseline and after 6 months of treatment

Secondary

MeasureTime frame
Disease Activity Score-28 (DAS-28) using ESR for Rheumatoid arthritis Timepoint: At baseline and after 6 months of treatment

Countries

India

Contacts

Public ContactDr Indrani Chakrabarti

National Institute of Homoeopathy

indrani.abc@gmail.com9433902555

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026